U
Ultimovacs
A pharmaceutical company developing novel immunotherapies against cancer
At a glance
- Status
- Listed
- Founded
- 2011
- Headquarters
- Oslo, Norway
- Listing
- IPO 2019
- Sector
- Biotech & Life Sciences
- Outcome tier
- Thoroughbred$100M+ revenue
News
Open roles
Ultimovacs in the Oslo ecosystem
The Ultimovacs office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
- UUUppsala University
Ownership
Share of equity by holder, from Dealroom's shareholder data. Stakes as last recorded by Dealroom (2026).
“Other / undisclosed” is the 52.5% not attributed to a named shareholder. See the full cap table on Dealroom →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
4 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ultimovacs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ultimovacs on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

